ArticleEULAR rheumatology open2026

Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised study.

Hiroaki Matsuno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.